KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Assets Average (2016 - 2025)

Historic Assets Average for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $3.6 billion.

  • Sarepta Therapeutics' Assets Average rose 212.21% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 billion, marking a year-over-year increase of 212.21%. This contributed to the annual value of $3.6 billion for FY2024, which is 1305.83% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Assets Average is $3.6 billion, which was up 212.21% from $3.6 billion recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Assets Average registered a high of $3.8 billion during Q4 2024, and its lowest value of $2.7 billion during Q3 2021.
  • Its 5-year average for Assets Average is $3.2 billion, with a median of $3.1 billion in 2023.
  • The largest annual percentage gain for Sarepta Therapeutics' Assets Average in the last 5 years was 2053.87% (2021), contrasted with its biggest fall of 525.05% (2021).
  • Over the past 5 years, Sarepta Therapeutics' Assets Average (Quarter) stood at $2.9 billion in 2021, then grew by 8.16% to $3.1 billion in 2022, then increased by 1.43% to $3.2 billion in 2023, then grew by 18.65% to $3.8 billion in 2024, then fell by 5.15% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q3 2025, $3.6 billion for Q2 2025, and $3.7 billion during Q1 2025.